NCT03207724View on ClinicalTrials.gov

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

November 21, 2019

Study Completion Date

October 27, 2020

Conditions

Pancreatic CancerCachexiaWeight Loss

Interventions

DRUG

Xilonix plus Onivyde and 5FU

Xilonix by IV

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Ipsen

INDUSTRY

collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Andrew Hendifar, MD

OTHER